Your dog was diagnosed with Splenic Hemangiosarcoma (Stage I–II). Accounts for 5–7% of all canine tumours; 25–100× higher incidence in dogs than humans. Most common splenic malignancy. Often presents as emergency haemoabdomen. Compare 8 treatment options for dogs including Splenectomy Alone, Splenectomy + Single-Agent Doxorubicin, Splenectomy + Single-Agent Carboplatin — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Splenic Hemangiosarcoma (Stage I–II)
Canine Oncology Treatment Guide
Splenic Hemangiosarcoma (Stage I–II)
Stage I (confined to spleen) – Stage II (ruptured with regional involvement)
Mesenchymal
About This Cancer
Hemangiosarcoma is an aggressive cancer arising from the cells that line blood vessels (vascular endothelium). In the spleen, it forms blood-filled tumours that can rupture without warning, causing life-threatening internal bleeding (haemoabdomen) — this emergency presentation is often the first sign of the disease. Stage I–II means the tumour is confined to the spleen without visible distant spread, though microscopic metastatic disease is presumed present in the vast majority of cases at diagnosis. Large and giant breeds, particularly Golden Retrievers and German Shepherd Dogs, are at highest risk. Even after surgical removal of the spleen, the cancer has almost always begun spreading microscopically, which is why follow-up chemotherapy is strongly recommended to delay the growth of these tiny secondary deposits.
Clinical Staging System for Canine Splenic HSA
Based on tumour confinement to spleen, rupture status, and presence of metastasis.
Prognostic Factors(3)
Minimum Workup(9 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.